Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
EyePoint, Inc.'s SEC filings document its business as a clinical-stage retinal-disease therapeutics company and record formal disclosures around DURAVYU, its investigational vorolanib intravitreal insert using Durasert E sustained-delivery technology. Form 8-K reports cover operating results, financial condition, cash resources, clinical-development updates for wet AMD and DME, investor presentations, and other material company events.
The company's proxy materials disclose governance, executive compensation, equity awards, shareholder voting matters, and board-related information. Additional filings record Nasdaq-listed common stock information, Regulation FD disclosures, forward-looking risk language, and legal-proceeding disclosures related to public statements about DURAVYU and its clinical results.
EyePoint, Inc. Schedule 13G discloses that Paradigm-related reporting persons hold disclosed stakes in EyePoint's common stock as of the close of business on 02/17/2026.
The filing shows Paradigm BioCapital Advisors (and related entities) with 4,192,261 shares ( 5.1%) and Paradigm BioCapital International Fund Ltd. with 3,694,542 shares ( 4.5%). The ownership percentages are calculated using 82,787,220 shares outstanding as of 10/30/2025.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions. On February 17, 2026, he exercised stock options and acquired 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares in an open-market transaction at $15.00 per share. Following these moves, he reported holding 85,313 stock options and no directly held common shares from this transaction. A disclosed option award vests 25% on January 3, 2026, with the remainder vesting monthly over the next three years.
Eyepoint, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II and Chen Yu reporting beneficial ownership of 3,572,335 shares of common stock, representing 4.3% of the class based on 82,787,220 shares outstanding as of October 30, 2025.
The reporting persons indicate they share voting and dispositive power over these shares through the fund structure and related entities, while disclaiming group status and beneficial ownership beyond their pecuniary interest. They also certify the holdings are passive and not intended to change or influence control of Eyepoint.
Adage Capital Management, L.P. and related parties report a 5.68% beneficial stake in EyePoint, Inc. common stock. They collectively hold 4,700,000 shares with shared voting and dispositive power and no sole authority. The percentage is based on 82,787,220 shares outstanding as of October 30, 2025.
The filing is made on Schedule 13G/A, indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control of EyePoint. The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross.
On January 6, 2026, EyePoint, Inc. director Nancy Lurker acquired 75,133 shares of common stock at $0.00 per share upon the vesting and settlement of previously granted restricted stock units. These units were part of an award that vests in three equal annual installments beginning January 6, 2024.
Following this transaction, she directly owned 294,346 shares of EyePoint common stock. An additional 126,889 shares are held indirectly by a family trust for the benefit of her children, for which her spouse is trustee, and she disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. President and CEO Jay S. Duker, who also serves as a director, reported routine equity activity on January 6, 2026 related to previously granted restricted stock units. A block of 20,793 restricted stock units converted into the same number of shares of common stock at an exercise price of $0.00, reflecting vesting of his equity award. To cover taxes on this vesting, 10,054 shares of common stock were withheld by EyePoint at a price of $16.86, and the filing specifies that no shares were sold in the market. After these transactions, Duker directly held 77,752 shares of common stock, and an additional 99,165 shares were reported as indirectly held by a family trust for the benefit of his children, for which he disclaims beneficial ownership.
EyePoint, Inc.’s Chief Financial Officer, Elston George, reported equity compensation activity involving restricted stock units and common shares. On January 6, 2026, 15,285 restricted stock units converted into 15,285 shares of common stock at an exercise price of $0.00, increasing his directly held common shares before withholding to 96,339.
On the same date, 4,487 of those common shares were withheld by the issuer at $16.86 per share to satisfy tax withholding obligations, rather than being sold in the market, leaving 91,852 common shares held directly. An additional 25,000 common shares are reported as held indirectly in a family trust for the benefit of his children, with the trust company as trustee and George disclaiming beneficial ownership of those securities.
EyePoint, Inc. Chief Medical Officer Ribeiro Ramiro reported exercising stock options and selling company shares. On January 5, 2026, Ramiro exercised an option to buy 29,250 shares of common stock at $8.26 per share, increasing his directly held common stock to 42,544 shares. That same day, he reported selling 42,544 shares of common stock at a weighted average price of $17.0957 per share, leaving him with no directly held common stock after the transactions.
Ramiro continues to hold 87,750 stock options following the reported activity. According to the filing, the option vests with 25% on January 3, 2026, with the remaining portion vesting monthly over the next three years, and carries an expiration date of January 3, 2035. The weighted average sale price reflects multiple trades between $16.68 and $17.51.
EyePoint, Inc. filed a current report to let investors know it has released a press release with preliminary cash information as of December 31, 2025 and other corporate updates. The company notes that these figures are preliminary, unaudited and may change once full audited financial statements for the year are completed. The press release is included as Exhibit 99.1, allowing the disclosed preliminary cash position and corporate developments to be incorporated by reference in future securities offerings or other SEC filings.
EyePoint, Inc. Chief Financial Officer Elston George reported multiple equity compensation transactions and related share issuances and tax withholdings in early January 2026. On January 2, 2026, he received 63,000 restricted stock units and a stock option for 126,000 shares, both at an exercise or conversion price of $0.00, with the RSUs vesting in three annual installments beginning January 2, 2027 and the option vesting 25% on January 2, 2027 and the remainder monthly over three years. On January 3 and 5, 2026, previously granted RSUs vested and converted into a total of 34,667 shares of common stock, with 6,324 and 4,403 shares withheld at prices of $17.48 and $17.43 to satisfy tax obligations, and no shares sold into the market. Following these transactions, he directly held 81,054 shares of common stock and derivative awards, and an additional 25,000 shares are held indirectly by a family trust for his children, for which he disclaims beneficial ownership.